Department of Joint Surgery and Sports Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, China; Department of Orthopedics, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China.
Department of Hematology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, China.
Acta Biomater. 2023 Sep 15;168:372-387. doi: 10.1016/j.actbio.2023.07.024. Epub 2023 Jul 21.
Osteoarthritis (OA) is a widespread clinical disease characterized by cartilage degeneration in middle-aged and elderly people. Currently, there is no effective treatment for OA apart from total joint replacement in advanced stages. Mesenchymal stem cells (MSCs) are a type of adult stem cell with diverse differentiation capabilities and immunomodulatory potentials. MSCs are known to effectively regulate the cartilage microenvironment, promote cartilage regeneration, and alleviate OA symptoms. As a result, they are promising sources of cells for OA therapy. Recent studies have revealed the presence of resident MSCs in synovial fluid, synovial membrane, and articular cartilage, which can be collected as knee joint-derived MSCs (KJD-MSC). Several preclinical and clinical studies have demonstrated that KJD-MSCs have great potential for OA treatment, whether applied alone, in combination with biomaterials, or as exocrine MSCs. In this article, we will review the characteristics of MSCs in the joints, including their cytological characteristics, such as proliferation, cartilage differentiation, and immunomodulatory abilities, as well as the biological function of MSC exosomes. We will also discuss the use of tissue engineering in OA treatment and introduce the concept of a new generation of stem cell-based tissue engineering therapy, including the use of engineering, gene therapy, and gene editing techniques to create KJD-MSCs or KJD-MSC derivative exosomes with improved functionality and targeted delivery. These advances aim to maximize the efficiency of cartilage tissue engineering and provide new strategies to overcome the bottleneck of OA therapy. STATEMENT OF SIGNIFICANCE: This research will provide new insights into the medicinal benefit of Joint resident Mesenchymal Stem Cells (MSCs), specifically on its cartilage tissue engineering ability. Through this review, the community will further realize promoting joint resident mesenchymal stem cells, especially cartilage progenitor/MSC-like progenitor cells (CPSC), as a preventive measure against osteoarthritis and cartilage injury. People and medical institutions may also consider cartilage derived MSC as an alternative approach against cartilage degeneration. Moreover, the discussion presented in this study will convey valuable information for future research that will explore the medicinal benefits of cartilage derived MSC.
骨关节炎(OA)是一种广泛存在的临床疾病,其特征是中老年人的软骨退化。目前,除了晚期的全关节置换外,OA 没有有效的治疗方法。间充质干细胞(MSCs)是一种具有多种分化能力和免疫调节潜力的成体干细胞。研究表明,MSCs 可以有效调节软骨微环境,促进软骨再生,缓解 OA 症状。因此,它们是 OA 治疗有前途的细胞来源。最近的研究表明,滑膜液、滑膜和关节软骨中存在固有 MSCs,可以作为膝关节来源的 MSCs(KJD-MSCs)收集。几项临床前和临床研究表明,KJD-MSCs 具有很大的 OA 治疗潜力,无论是单独应用、与生物材料联合应用还是作为外分泌 MSCs。在本文中,我们将回顾关节中 MSCs 的特征,包括其细胞学特征,如增殖、软骨分化和免疫调节能力,以及 MSC 外泌体的生物学功能。我们还将讨论组织工程在 OA 治疗中的应用,并介绍新一代基于干细胞的组织工程治疗的概念,包括使用工程、基因治疗和基因编辑技术来创建具有改进功能和靶向递送的 KJD-MSCs 或 KJD-MSC 衍生的外泌体。这些进展旨在最大限度地提高软骨组织工程的效率,并提供克服 OA 治疗瓶颈的新策略。
意义声明:本研究将为关节驻留间充质干细胞(MSCs)的药用功效提供新的见解,特别是其软骨组织工程能力。通过这项研究,科学界将进一步认识到促进关节驻留间充质干细胞,特别是软骨祖细胞/MSC 样祖细胞(CPSC),作为预防骨关节炎和软骨损伤的一种手段。人们和医疗机构也可能会考虑将软骨来源的 MSC 作为一种替代方法来治疗软骨退化。此外,本研究中提出的讨论将为未来探索软骨来源的 MSC 的药用功效的研究提供有价值的信息。
Acta Biomater. 2023-9-15
Front Bioeng Biotechnol. 2020-10-14
Curr Pharm Biotechnol. 2019
J Orthop Translat. 2025-8-26
Stem Cell Res Ther. 2025-7-9
J Multidiscip Healthc. 2025-6-24
Int J Mol Sci. 2025-5-5
Front Bioeng Biotechnol. 2025-4-24